Administration of Rg100204, an aquaporin-9 (AQP9) inhibitor, reduced pancreatic and lung damage in animals with AP by interacting with the NF-κB and Nrf2 pathways and thus suppressing NLRP3 activation [99]. Here, AQP9 is linked to alkaline phosphatase measurement.